Adv Mater:金-钆复合纳米载体协助化疗药物突破肿瘤组织内部的病理屏障并实现可视化检测

2017-05-28 佚名 MaterialsViews

化疗一直是癌症治疗最常用的手段之一。但在临床治疗中,化疗效果往往并不理想。对于内部间质高压、乏氧的实体瘤,化疗药物不仅需要通过肿瘤血管的生理屏障进入肿瘤组织,而且需要穿越肿瘤组织内的病理屏障到达肿瘤内部才能获得更好的治疗效果。大量研究表明,由于特定的尺寸,纳米载药系统可以通过增强的渗透和滞留(enhanced permeability and retention,EPR)效应通过肿瘤血管的生理屏障

化疗一直是癌症治疗最常用的手段之一。但在临床治疗中,化疗效果往往并不理想。对于内部间质高压、乏氧的实体瘤,化疗药物不仅需要通过肿瘤血管的生理屏障进入肿瘤组织,而且需要穿越肿瘤组织内的病理屏障到达肿瘤内部才能获得更好的治疗效果。大量研究表明,由于特定的尺寸,纳米载药系统可以通过增强的渗透和滞留(enhanced permeability and retention,EPR)效应通过肿瘤血管的生理屏障进入肿瘤组织。当前一个主要问题是化疗药物(包括纳米载药系统)很难穿越肿瘤组织内的病理屏障,在肿瘤组织内部的分布非常有限,从而限制了化疗的疗效。此外,化疗药物缺乏对肿瘤组织的识别,对正常组织具有明显的毒副作用:比如盐酸阿霉素(Dox)具有明显的心脏毒性。

在纳米生物效应分析的研究过程中,国家纳米科学中心赵宇亮及其同事发现,金纳米材料由于良好的生物相容性、特殊的光学和光热转化性质、表面易于功能化。一些金纳米材料(比如金纳米棒),在近红外激光照射下能产生局域化的热,一方面可以用于肿瘤光热治疗,另一方面可以驱动药物释放。此外,金纳米材料表面修饰核磁造影剂钆可以实现多模态成像检测与分析。为此,赵宇亮研究员领导的研究团队,设计了一种具有化疗药物和钆造影剂高负载性能的金-钆复合纳米载体,并在低功率的近红外激光照射下,利用金-钆复合纳米载体产生的温和的热刺激,协助药物穿越肿瘤内部的病理屏障,进而提高化疗疗效。该载体的钆负载量达到了每个纳米颗粒上有1.5*106个钆离子,且和商用Gd-DTPA造影剂相比,该载体的弛豫率r1提高了3.6倍,因此具有更好的T1成像效果。小鼠静脉注射载体后,结合计算机断层扫描(CT)和核磁共振成像(MRI),可以清晰地观察到肿瘤的大小、位置、轮廓以及血管造影。在近红外激光照射下,载体本身产生的局域化的、温和的热(42-43℃),显示出了提高的病理学渗透和滞留(Enhanced Pathological Permeability and Retention,EPPR)效应:从肿瘤内部(4.8 mm)到肿瘤边缘(0 mm),载药材料的积累量分别提高到 2.8~3.9倍。载体表面修饰的透明质酸有效提高了三阴性乳腺癌MDA-MB-231细胞对载药材料的摄入。透明质酸可被肿瘤微环境和肿瘤细胞内溶酶体中的透明质酸酶降解,产生了酶响应的药物释放行为。由于该载药材料在肿瘤组织内部的渗透性明显提高,并且能在肿瘤位点特异性地释放药物,因此该载药材料在动物水平显示出提高的化疗疗效,并克服了Dox引起的毒性。

该项研究首次提出了EPPR(Enhanced Pathological Permeability and Retention)效应,为体内药物输运过程中如何克服病理学屏障提供了新的思路。金-钆复合纳米载体的化学设计,为获得高灵敏的多模态成像指导的同步治疗、提高肿瘤的治疗疗效,提供了新的方法。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1942844, encodeId=4d341942844fa, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 12 17:36:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075750, encodeId=337f20e57502d, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jan 24 06:36:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645432, encodeId=2b1d16454320d, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jun 30 08:36:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506707, encodeId=80ec1506e07fb, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581746, encodeId=2ceb1581e465f, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204172, encodeId=7c862041e243, content=涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue May 30 00:32:29 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203747, encodeId=8d41203e47b7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon May 29 00:19:19 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1942844, encodeId=4d341942844fa, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 12 17:36:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075750, encodeId=337f20e57502d, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jan 24 06:36:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645432, encodeId=2b1d16454320d, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jun 30 08:36:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506707, encodeId=80ec1506e07fb, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581746, encodeId=2ceb1581e465f, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204172, encodeId=7c862041e243, content=涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue May 30 00:32:29 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203747, encodeId=8d41203e47b7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon May 29 00:19:19 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1942844, encodeId=4d341942844fa, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 12 17:36:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075750, encodeId=337f20e57502d, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jan 24 06:36:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645432, encodeId=2b1d16454320d, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jun 30 08:36:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506707, encodeId=80ec1506e07fb, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581746, encodeId=2ceb1581e465f, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204172, encodeId=7c862041e243, content=涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue May 30 00:32:29 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203747, encodeId=8d41203e47b7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon May 29 00:19:19 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-06-30 mei539
  4. [GetPortalCommentsPageByObjectIdResponse(id=1942844, encodeId=4d341942844fa, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 12 17:36:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075750, encodeId=337f20e57502d, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jan 24 06:36:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645432, encodeId=2b1d16454320d, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jun 30 08:36:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506707, encodeId=80ec1506e07fb, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581746, encodeId=2ceb1581e465f, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204172, encodeId=7c862041e243, content=涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue May 30 00:32:29 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203747, encodeId=8d41203e47b7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon May 29 00:19:19 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1942844, encodeId=4d341942844fa, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 12 17:36:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075750, encodeId=337f20e57502d, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jan 24 06:36:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645432, encodeId=2b1d16454320d, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jun 30 08:36:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506707, encodeId=80ec1506e07fb, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581746, encodeId=2ceb1581e465f, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204172, encodeId=7c862041e243, content=涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue May 30 00:32:29 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203747, encodeId=8d41203e47b7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon May 29 00:19:19 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1942844, encodeId=4d341942844fa, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 12 17:36:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075750, encodeId=337f20e57502d, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jan 24 06:36:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645432, encodeId=2b1d16454320d, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jun 30 08:36:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506707, encodeId=80ec1506e07fb, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581746, encodeId=2ceb1581e465f, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204172, encodeId=7c862041e243, content=涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue May 30 00:32:29 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203747, encodeId=8d41203e47b7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon May 29 00:19:19 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-05-30 luominglian113

    涨知识了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1942844, encodeId=4d341942844fa, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Jul 12 17:36:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075750, encodeId=337f20e57502d, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jan 24 06:36:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645432, encodeId=2b1d16454320d, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jun 30 08:36:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506707, encodeId=80ec1506e07fb, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581746, encodeId=2ceb1581e465f, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Tue May 30 12:36:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204172, encodeId=7c862041e243, content=涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue May 30 00:32:29 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203747, encodeId=8d41203e47b7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon May 29 00:19:19 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-05-29 189****7206

    学习了谢谢分享。

    0

相关资讯

Nanomedicine:纳米载体跨越血脑屏障靶向治疗脑癌

(图片摘自www.sciencealert.com) 最近,科学家们在探索脑癌治疗手段的路上又有了新的突破。起初他们认为这一发现可能是一个测量错误,但事实证明该结果是真实的,而且将对脑癌的治疗产生巨大的影响。 通过利用纳米载体将化学药物定向运输到大脑中,科学家们能够将脑部的肿瘤细胞大量杀灭。 目前该技术仅仅在小鼠水平得到了验证,但如果能够同样适用于人体的话,将会导致新的治疗脑癌的疗法的产

Small:安全可靠的新型介孔氧化钽纳米载体用于放化疗协同治疗

如今,癌症仍然是全世界最致命的疾病之一,每年都有超过1000万的新病例被确诊。癌症的主要治疗方法包括手术、化疗和放疗已被广泛应用于临床,但却都有着各自的缺陷。例如化疗的毒副作用以及放疗肿瘤部位辐射吸收效率低等。近年来,放化疗联合治疗(chemo-radiotherapy)在临床试验中被广泛应用,并且大量的临床治疗结果显示,相比于单一的放疗,联合治疗对肿瘤的杀伤作用更为有效。尽放化疗有着这些优势,但

Sci Rep:上海中医药大学研究人员设计新型纳米载体提高多西紫杉醇的口服抗肿瘤效果

多西紫杉醇是现有药物中治疗转移乳腺癌和非小细胞肺癌最有效的化疗药物之一。但因其具有高度亲脂性,不溶于水,又受到P-糖蛋白的外排,生物利用度低,口服制剂至今未能推广,临床上使用的注射剂常出现剧烈的过敏反应并需要联合使用皮质激素;此外作为抗癌药,多西紫杉醇本身具有较大的不良反应,这些因素都极大地限制了其进一步应用。近日,上海中医药大学交叉科学研究院胡凯莉副研究员在国际期刊Scientific Repr